Artal Group’s PMV Pharmaceuticals PMVP Stock Holding History

Artal Group’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-200,000	Closed	-$7.1M	–	148
2020 Q3	$7.1M	Buy	+200,000	New	+$7.36M	0.17%	86

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group's PMVP Position: Q4 2020 in Review

Artal Group sold out of PMV Pharmaceuticals (PMVP) in Q4 2020, closing a stake of 200,000 shares — an estimated $7.1M sold.

Artal Group first reported a position in PMVP in Q3 2020 and held it in 1 quarter. The position peaked at $7.1M in Q3 2020. 73 funds tracked by Wall St. Rank hold PMVP as of Q4 2020.

Artal Group reported no remaining PMV Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Artal Group sold 200,000 PMV Pharmaceuticals shares in Q4 2020, an estimated $7.1M.
Artal Group first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 1 quarter.
Artal Group's PMV Pharmaceuticals position peaked at $7.1M in Q3 2020.
73 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.